Position in GYRE
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$82,539
+$9,090 QoQ
Shares Held
12,525
+18.9% QoQ
Ownership
0.011%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#27
of 60 holders
Holding Since
Jun 2024
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in GYRE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026BANK OF AMERICA CORP /DE/ holds $10,144,297,346 across 338 Biotechnology names. GYRE ranks #315 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
3,039,178 | $1,509,650,884 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
1,291,053 | $805,023,185 | |
| 3 | CYTK |
Cytokinetics Inc
|
4,635,709 | $394,916,048 | |
| 4 | ARGX |
Argenx SE
|
400,234 | $371,325,094 | |
| 5 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
994,476 | $299,367,107 | |
| 6 | JAZZ |
Jazz Pharmaceuticals plc
|
1,136,091 | $273,763,844 | |
| 7 | TVTX |
Travere Therapeutics, Inc.
|
4,568,341 | $259,527,450 | |
| 8 | RPRX |
Royalty Pharma plc
|
4,149,422 | $232,658,090 |
All Filings in GYRE
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $82,539 | 12,525 | Shares | Defined | 2026-08-14 | |
| 2026-03-31 | $73,449 | 10,538 | Shares | Defined | 2026-05-18 | |
| 2025-12-31 | $68,897 | 9,759 | Shares | Defined | 2026-02-17 | |
| 2025-09-30 | $49,884 | 6,687 | Shares | Defined | 2026-02-03 | |
| 2025-06-30 | $46,135 | 6,277 | Shares | Defined | 2025-08-14 | |
| 2025-03-31 | $37,635 | 4,875 | Shares | Defined | 2025-05-15 | |
| 2024-12-31 | $83,936 | 6,937 | Shares | Defined | 2025-02-14 | |
| 2024-09-30 | $61,959 | 4,941 | Shares | Defined | 2024-11-14 | |
| 2024-06-30 | $59,280 | 4,969 | Shares | Defined | 2024-08-14 | |
| No filing history on record for this holder in this stock. | ||||||